REQUIP*21CPR 0,5MG ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease1

6. Parkinson disease


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-005423-34-IT
(EUCTR)
08/05/200603/10/2006A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release IR Tablets or Ropinirole Prolonged Release / Extended Release PR/XR Tablets in Advanced Stage Parkinson s Disease Subjects who are not Adequately Controlled on L-dopa. - NDA Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release IR Tablets or Ropinirole Prolonged Release / Extended Release PR/XR Tablets in Advanced Stage Parkinson s Disease Subjects who are not Adequately Controlled on L-dopa. - ND Parkinson disease
MedDRA version: 6.1;Level: PT;Classification code 10061536
Product Name: ropinirole PR/XR tablets
Product Code: SKF-101468A
INN or Proposed INN: Ropinirole
Trade Name: REQUIP*21CPR 0,25MG
INN or Proposed INN: Ropinirole
Product Name: ropinirole PR/XR tablets
Product Code: SKF-101468A
INN or Proposed INN: Ropinirole
Product Name: ropinirole PR/XR tablets
Product Code: SKF-101468A
INN or Proposed INN: Ropinirole
Trade Name: REQUIP*21CPR 0,5MG
INN or Proposed INN: Ropinirole
Trade Name: REQUIP*21CPR 1MG
INN or Proposed INN: Ropinirole
GlaxoSmithKline R DNULLNot RecruitingFemale: yes
Male: yes
516Hungary;United Kingdom;Czech Republic;Germany;Spain;Italy